EORTC/TROG 01.03 - Glioblastoma/Temozolomide - 26981/22981

By w.paterson
14 August, 2021
0 Comments

Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. A Randomized Phase III Study

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research

23 October, 2024

New Cancer Australia grant supports TROG work

23 October 2024: TROG Cancer Research is thrilled to

15 October, 2024

Diversity, equity and inclusion at heart of TROG work

15 October 2024: TROG Cancer Research has made a

Join us to raise $20,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. A Randomized Phase III Study

TROG 01.04 – Rectal (Phase III)

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

Related Post

New Cancer Australia grant supports TROG work

Diversity, equity and inclusion at heart of TROG work

Join us to raise $20,000

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. A Randomized Phase III Study

TROG 01.04 – Rectal (Phase III)

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

Related Post

New Cancer Australia grant supports TROG work

Diversity, equity and inclusion at heart of TROG work

Join us to raise $20,000